<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04796350</url>
  </required_header>
  <id_info>
    <org_study_id>AGN-CIP-100</org_study_id>
    <nct_id>NCT04796350</nct_id>
  </id_info>
  <brief_title>Study of AGN1 LOEP to Prevent Secondary Hip Fractures</brief_title>
  <acronym>RESTORE</acronym>
  <official_title>Randomized Controlled Study of a Local Osteo-Enhancement Procedure (LOEP) to Prevent Secondary Hip Fractures in Osteoporotic Women Undergoing Treatment of Index Hip Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AgNovos Healthcare, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Avania</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>CMIC Co, Ltd. Japan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baim Institute for Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BioClinica, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AgNovos Healthcare, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized controlled trial to evaluate AGN1 to prevent secondary hip fractures in&#xD;
      osteoporotic women undergoing treatment of index hip fractures. Up to 2400 subjects will be&#xD;
      randomized between a treatment group and a control group. Subjects will be followed for a&#xD;
      minimum of 5 years after undergoing hip fracture repair surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an event driven, randomized, controlled, prospective, single blinded, multi-national&#xD;
      study.&#xD;
&#xD;
      This study is designed to demonstrate that the AGN1 LOEP treatment can reduce the incidence&#xD;
      of secondary hip fractures in subjects presenting with an index hip fracture and undergoing&#xD;
      hip fracture repair surgery. Subjects presenting with an index fragility hip fracture who&#xD;
      will undergo hip fracture repair will be enrolled. Subjects will be randomized 1:1 into the&#xD;
      following two study groups:&#xD;
&#xD;
        1. Treated Group - receives standard of care to repair the index hip fracture and AGN1 LOEP&#xD;
           treatment on the target unfractured contralateral hip&#xD;
&#xD;
        2. Control Group - receives standard of care to repair the index hip fracture and no AGN1&#xD;
           LOEP treatment on the target unfractured contralateral hip&#xD;
&#xD;
      AGN1 LOEP is an elective procedure that will be performed immediately following hip fracture&#xD;
      repair.&#xD;
&#xD;
      Subjects will be followed through scheduled visits conducted at 6 weeks, 6 months, and every&#xD;
      6 months thereafter for a minimum of 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of secondary fragility hip fractures</measure>
    <time_frame>Interim Analysis, approximately 30 Months</time_frame>
    <description>Comparison of incidence of secondary fragility hip fractures in the target hip among the Treated Group vs. Control Group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Interim Analysis, approximately 30 Months</time_frame>
    <description>Comparison of incidence of AEs and SAEs among the Treated Group vs. Control Group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Areal bone mineral density (aBMD)</measure>
    <time_frame>12 months and 24 months</time_frame>
    <description>Total hip areal bone mineral density in target hips of the Treated Group compared to the Control Group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trabecular Bone Score (TBS)</measure>
    <time_frame>12 months and 24 months</time_frame>
    <description>Continuous densitometry measure of the target hip bone of the Treated Group compared to the Control Group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2400</enrollment>
  <condition>Fragility Fracture</condition>
  <condition>Hip Fractures</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Treated group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject receives standard of care to repair the index hip fracture and AGN1 LOEP treatment on the target unfractured contralateral hip</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subject receives standard of care to repair the index hip fracture and no AGN1 LOEP treatment on the target unfractured contralateral hip</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AGN1 LOEP treatment</intervention_name>
    <description>the implantation site is injected with the AGN1 implant material</description>
    <arm_group_label>Treated group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is a postmenopausal female at least 1-year post menses and at least 65 years&#xD;
             of age.&#xD;
&#xD;
          2. Subject presents with a low-energy index fragility hip fracture in one hip and will&#xD;
             undergo surgical repair of the fractured hip.&#xD;
&#xD;
          3. Subject has at least one of the following additional risk factors for a secondary hip&#xD;
             fracture (as determined by subject or legally authorized representative (LAR)&#xD;
             interview or medical record review):&#xD;
&#xD;
               -  Documented falls assessment indicating subject is at moderate or high risk of&#xD;
                  falls&#xD;
&#xD;
               -  Falls history (2 or more falls in the previous 12 months)&#xD;
&#xD;
               -  History of vertigo, dizziness, or postural hypotension&#xD;
&#xD;
               -  Documented T-score &lt; -2.5 at the hip&#xD;
&#xD;
               -  Taking more than 3 daily prescription medications&#xD;
&#xD;
               -  Visual impairment as confirmed by one of the following:&#xD;
&#xD;
                    -  Subject reports difficulty seeing&#xD;
&#xD;
                    -  Lack of depth perception or vision loss in one eye&#xD;
&#xD;
                    -  Macular degeneration&#xD;
&#xD;
                    -  Cataracts&#xD;
&#xD;
               -  Prior non-hip fragility fracture&#xD;
&#xD;
               -  Cognitive frailty as assessed by SPMSQ (mild or moderate cognitive impairment) or&#xD;
                  delirium&#xD;
&#xD;
               -  Parkinson's disease stage 3 or 4&#xD;
&#xD;
               -  10-year hip fracture probability &gt;15% using the FRAX® Fracture Risk Assessment&#xD;
                  Tool of the clinical site country&#xD;
&#xD;
          4. Subject is expected to be ambulatory after the hip fracture repair procedure.&#xD;
&#xD;
          5. Informed consent is provided by the subject or the subject's LAR.&#xD;
&#xD;
          6. The subject's willingness, ability, and commitment to participate in screening,&#xD;
             treatment, and all follow-up evaluations for the full duration of the study has been&#xD;
             documented.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject hospital admission is &gt; 24 hours from the time of the index hip fracture.&#xD;
&#xD;
          2. Subject was dependent on the use of a wheelchair or was bedridden prior to the index&#xD;
             hip fracture.&#xD;
&#xD;
          3. Subject is currently enrolled in another clinical study.&#xD;
&#xD;
          4. Subject has a history of hip surgery or previous hip fracture on the target&#xD;
             unfractured hip contralateral to the index hip fracture.&#xD;
&#xD;
          5. Subject has one or more new fractures in addition to the index hip fracture at&#xD;
             admission.&#xD;
&#xD;
          6. Subject has an infection at the LOEP intended treatment site or has non-intact skin or&#xD;
             acute traumatic injuries with open wounds close to the area of intended LOEP&#xD;
             treatment.&#xD;
&#xD;
          7. Subject has a progressive increase in undiagnosed pain in the target hip contralateral&#xD;
             to the index fractured hip over the previous 3 months that in the opinion of the&#xD;
             Investigator may suggest underlying bone or joint pathology on the unfractured side.&#xD;
&#xD;
          8. Subject has radiological evidence of gross bony or joint pathology of the hip,&#xD;
             including signs predictive of atypical femoral fractures (e.g. cortical beaking), or&#xD;
             has been diagnosed and/or treated for atypical femoral fractures.&#xD;
&#xD;
          9. Subject is at ASA Class IV, V, or VI.&#xD;
&#xD;
         10. Subject has a history of metabolic bone disease other than osteoporosis (e.g., Paget's&#xD;
             disease, renal osteodystrophy, or osteomalacia).&#xD;
&#xD;
         11. Subject has a history of Pott's disease.&#xD;
&#xD;
         12. Subject has a history of any invasive malignancy (except nonmelanoma skin cancer),&#xD;
             unless treated with curative intent and with no clinical signs or symptoms of the&#xD;
             malignancy for 5 years.&#xD;
&#xD;
         13. Subject has chronic cardiac insufficiency or severe cardiovascular disease as assessed&#xD;
             by a subject or LAR interview to be NYHA Class III or IV or has an implanted&#xD;
             pacemaker.&#xD;
&#xD;
         14. Subject has a history of cardiovascular events (e.g. stroke, transient ischemic&#xD;
             attack, myocardial infarction, unstable angina, pulmonary embolus, deep vein&#xD;
             thrombosis, ventricular tachycardia, or atrial fibrillation) in the last 3 months.&#xD;
&#xD;
         15. Subject is on oral or parenteral immuno-suppressive drugs.&#xD;
&#xD;
         16. Subject has uncontrolled diabetes mellitus.&#xD;
&#xD;
         17. Subject has Hb ≤ 10 g/dL at admission.&#xD;
&#xD;
         18. Subject has severe renal insufficiency defined as an estimated glomerular filtration&#xD;
             rate (eGFR) ≤ 30 mL/min.&#xD;
&#xD;
         19. Subject has albumin corrected serum calcium levels outside the normal laboratory range&#xD;
             or has a pre-existing calcium metabolism disorder (e.g. hypercalcemia).&#xD;
&#xD;
         20. Subject has a Parker Mobility Score ≤ 5.&#xD;
&#xD;
         21. Subject has severe cognitive impairment as assessed by SPMSQ.&#xD;
&#xD;
         22. Subject has known allergies to calcium-based bone void fillers.&#xD;
&#xD;
         23. In the judgement of the Investigator, the subject is not a good study candidate (e.g.,&#xD;
             inability to maintain follow-up schedule, comorbidity or poor general physical/mental&#xD;
             health, or drug or alcohol abuse issues).&#xD;
&#xD;
         24. Subject fails pre-operative or intraoperative eligibility criteria as specified in&#xD;
             section 7.4.2. of the clinical investigation plan.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adam Lowe</last_name>
    <phone>+1-240-676-2200</phone>
    <email>restore@agnovos.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Innsbruck Hospital</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RESTORE Study</last_name>
      <email>restore@agnovos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Deventer Hospital</name>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RESTORE Study</last_name>
      <email>restore@agnovos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Isala Hospital</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RESTORE Study</last_name>
      <email>restore@agnovos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RESTORE Study</last_name>
      <email>restore@agnovos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valladolid University Clinic Hospital</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RESTORE Study</last_name>
      <email>restore@agnovos.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://jrct.niph.go.jp/en-latest-detail/jRCT2022210008</url>
    <description>Japan Registry of Clinical Trials</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>Hip Fracture</keyword>
  <keyword>Fragility Fracture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

